FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jon Curwen

Research Profile

Chemicals & Drugs

Living Beings

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Tim P Green; Judith Hargreaves; Laurent F A Hennequin; D Mark Hickinson; Geoffrey A Holdgate; Vivien Jacobs; Armelle Logie; Patrick A Plé; Walter H J Ward; Robin Whittaker; Robert W Wilkinson; Jack Allen; Alun Bermingham; Brigitte Boyer; Neil Carragher; Jon O Curwen; Barry R Davies; Paul Elvin; Mike Fennell; Gerard F Costello
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Jon O Curwen; Stephen R Wedge
The use and refinement of rodent models in anti-cancer drug discovery: a review.
Laurent F A Hennequin; Jack Allen; Jason Breed; Jon O Curwen; Michael Fennell; Tim P Green; Christine Lambert-Van Der Brempt; Rémy Morgentin; Richard A Norman; Annie Olivier; Ludovic R Otterbein; Patrick A Plé; Nicolas Warin; Gerard Costello
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jon Curwen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Tim P Green; Judith Hargreaves; Laurent F A Hennequin; D Mark Hickinson; Geoffrey A Holdgate; Vivien Jacobs; Armelle Logie; Patrick A Plé; Walter H J Ward; Robin Whittaker; Robert W Wilkinson; Jack Allen; Alun Bermingham; Brigitte Boyer; Neil Carragher; Jon O Curwen; Barry R Davies; Paul Elvin; Mike Fennell; Gerard F Costello
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Molecular oncology 2009;3(3):248-61.
2009: Jon O Curwen; Stephen R Wedge
The use and refinement of rodent models in anti-cancer drug discovery: a review.
Alternatives to laboratory animals : ATLA 2009;37(2):173-80.
2006: Laurent F A Hennequin; Jack Allen; Jason Breed; Jon O Curwen; Michael Fennell; Tim P Green; Christine Lambert-Van Der Brempt; Rémy Morgentin; Richard A Norman; Annie Olivier; Ludovic R Otterbein; Patrick A Plé; Nicolas Warin; Gerard Costello
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
Journal of medicinal chemistry 2006;49(22):6465-88.
2005: Stephen R Wedge; Jane Kendrew; Laurent F A Hennequin; Paula J Valentine; Simon T Barry; Sandra R Brave; Neil R Smith; Neil H James; Michael Dukes; Jon O Curwen; Rosemary Chester; Janet A Jackson; Sarah J Boffey; Lyndsey L Kilburn; Sharon Barnett; Graham H P Richmond; Peter F Wadsworth; Mike Walker; Alison L Bigley; Sian T Taylor; Lee Cooper; Sarah Beck; Juliane M Jürgensmeier; Donald J Ogilvie
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
Cancer research 2005;65(10):4389-400.
2004: Patrick A Plé; Tim P Green; Laurent F A Hennequin; Jon O Curwen; Michael Fennell; Jack Allen; Christine Lambert-Van Der Brempt; Gerard Costello
Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src.
Journal of medicinal chemistry 2004;47(4):871-87.
2002: Stephen R Wedge; Donald J Ogilvie; Michael Dukes; Jane Kendrew; Rosemary Chester; Janet A Jackson; Sarah J Boffey; Paula J Valentine; Jon O Curwen; Helen L Musgrove; George A Graham; Gareth D Hughes; Andrew P Thomas; Elaine S E Stokes; Brenda Curry; Graham H P Richmond; Peter F Wadsworth; Alison L Bigley; Laurent F A Hennequin
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
Cancer research 2002;62(16):4645-55.
2002: Laurent F A Hennequin; Elaine S E Stokes; Andrew P Thomas; Craig Johnstone; Patrick A Plé; Donald J Ogilvie; Michael Dukes; Stephen R Wedge; Jane Kendrew; Jon O Curwen
Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.
Journal of medicinal chemistry 2002;45(6):1300-12.
2000: Stephen R Wedge; Donald J Ogilvie; Michael Dukes; Jane Kendrew; Jon O Curwen; Laurent F A Hennequin; Andrew P Thomas; Elaine S E Stokes; Brenda Curry; Graham H P Richmond; Peter F Wadsworth
ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.
Cancer research 2000;60(4):970-5.
1999: Laurent F A Hennequin; Andrew P Thomas; C Johnstone; Elaine S E Stokes; Patrick A Plé; J J Lohmann; Donald J Ogilvie; Michael Dukes; Stephen R Wedge; Jon O Curwen; Jane Kendrew; Christine Lambert-Van Der Brempt
Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.
Journal of medicinal chemistry 1999;42(26):5369-89.